Champions Oncology (FRA:2I3) Institutional Ownership: 4.45% (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2I3 Champions Oncology Inc FRA:2I3
64 GF Score
Price €4.46
GF Value €5.64
! 3 Warning Signs
View Full Analysis

What is Champions Oncology Institutional Ownership?

Champions Oncology FRA:2I3 -3.88% 64 Institutional Ownership is 4.45% as of Aug. 02, 2026. GuruFocus rates FRA:2I3 with a GF Score™ of 64/100 and a GF Value™ of €5.64. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Champions Oncology's institutional ownership is 4.45%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Champions Oncology's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Champions Oncology's Float Percentage Of Total Shares Outstanding is 49.00%.

Champions Oncology Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Champions Oncology's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology Institutional Ownership Chart

Champions Oncology Historical Data

The historical data trend for Champions Oncology can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 5.02 4.98 4.98 4.48 4.49 4.49 4.52 4.44 4.40 4.45
FRA:2I3
64GF Score
Champions Oncology Inc FRA:2I3
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 4.45% mean?
Champions Oncology (FRA:2I3) has a Institutional Ownership of 4.45% as of Aug. 02, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Champions Oncology and its competitors.
Is Champions Oncology's Institutional Ownership too high?
Champions Oncology's current Institutional Ownership is 4.45%. Overall, Champions Oncology has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Institutional Ownership compare to RLYB and NRXS?
Champions Oncology's Institutional Ownership of 4.45% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Champions Oncology and its competitors. Champions Oncology's current Institutional Ownership is 4.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Champions Oncology (FRA:2I3) has a current Institutional Ownership of 4.45%. The stock's GF Value™ is €5.64, compared to a current price of €4.46 — trading 20.9% below its estimated fair value. The current Institutional Ownership is 4.45%. Champions Oncology's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Champions Oncology (FRA:2I3), the current Institutional Ownership is 4.45% as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (FRA:2I3) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of €4.46 is trading 20.9% below its estimated GF Value™ of €5.64.

Key valuation signals for FRA:2I3:

  • Institutional Ownership: 4.45%
  • GF Value™: €5.64 vs. price of €4.46 (20.9% below fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the FRA:2I3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Champions Oncology Business Description

Other Exchanges CSBR:USA
Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score

Get the complete analysis for FRA:2I3

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.46
Price
€5.64
GF Value